Immunovo B.V.

Product portfolio

PEPA10/RFASE Immunebooster

Product

Safe And Effective Adjuvants: The Missing Link In addition to synthetic peptide technology, the immune response against relatively weak ‘self’ antigens requires maximization to obtain the desired effect in all...

View Details

Gastrine

Product

Patients with pancreatic cancer usually present with advanced disease and have a poor prognosis. ImmuNovo’s approach is to develop a therapeutic vaccine, based on gastrin, that will lead to the...

View Details

VEGF

Product

Immunovo’s Immune Activation System “IAS” A Novel Approach to Angiogenesis Inhibition Immunotherapy as a treatment modality in oncology has recently gained solid ground with the use of monoclonal antibodies (MAbs)...

View Details

GnRH

Product

Therapeutic vaccines are directed against ‘self’ proteins. ‘Self’ proteins as such make poor immunogens and often do not induce antibodies at all. ImmuNovo has found ways around this obstacle. Therapeutic...

View Details
Back to Top